Coherus Oncology (CHRS) EBITDA Margin Growth (5y) (2019 - 2026)
Powered by 
Analysis
Coherus Oncology (CHRS) EBITDA Margin Growth (5y) (2019 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn |
| 10 | Coherus Oncology | 209.00 Mn | 103.70 Mn | 10.07 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -19,841.00 |
| Mar 31, 2026 | -9,212.00 |
| Dec 31, 2025 | -37,477.00 |
| Sep 30, 2025 | -41,283.00 |
| Jun 30, 2025 | -49,173.00 |
| Mar 31, 2025 | -63,308.00 |
| Dec 31, 2024 | -62,325.00 |
| Sep 30, 2024 | -82,063.00 |
| Jun 30, 2024 | -41,782.00 |
| Mar 31, 2024 | -289,230.00 |
| Jun 30, 2022 | 397,240.00 |
| Mar 31, 2022 | 4.48 Mn |
| Dec 31, 2021 | 864,988.00 |
| Sep 30, 2021 | -9,171.00 |
| Jun 30, 2021 | 41,838.00 |
| Mar 31, 2021 | 31,913.00 |
| Dec 31, 2020 | 52,681.00 |
| Sep 30, 2020 | 102,337.00 |
| Jun 30, 2020 | 90,591.00 |
| Mar 31, 2020 | 66,767.00 |